Morgan Stanley
KITE

Morgan Stanley’s Kite Pharma, Inc. KITE Stock Holding History

Morgan Stanley’s Portfolio KITE Stock Details KITE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-489,605
Closed -$88M – 6853
2017
Q3 		$88M Buy
489,605
+345,039
+239% +$48.1M 0.03% 626
2017
Q2 		$15M Buy
144,566
+9,776
+7% +$798K ﹤0.01% 1782
2017
Q1 		$10.6M Sell
134,790
-7,336
-5% -$454K ﹤0.01% 2139
2016
Q4 		$6.37M Buy
142,126
+108,493
+323% +$5.32M ﹤0.01% 2745
2016
Q3 		$1.88M Buy
33,633
+14,050
+72% +$783K ﹤0.01% 3545
2016
Q2 		$979K Sell
19,583
-3,091
-14% -$152K ﹤0.01% 3985
2016
Q1 		$1.04M Buy
22,674
+1,046
+5% +$50.7K ﹤0.01% 3908
2015
Q4 		$1.33M Buy
21,628
+739
+4% +$52K ﹤0.01% 3833
2015
Q3 		$1.16M Sell
20,889
-12,249
-37% -$770K ﹤0.01% 3992
2015
Q2 		$2.02M Sell
33,138
-20,703
-38% -$1.18M ﹤0.01% 3616
2015
Q1 		$3.11M Buy
53,841
+27,231
+102% +$1.83M ﹤0.01% 3174
2014
Q4 		$1.53M Buy
26,610
+4,313
+19% +$182K ﹤0.01% 3778
2014
Q3 		$636K Buy
+22,297
New +$552K ﹤0.01% 4403

Morgan Stanley's KITE Position: Q4 2017 in Review

Morgan Stanley sold out of Kite Pharma, Inc. (KITE) in Q4 2017, closing a stake of 489,605 shares — an estimated $88M sold.

Morgan Stanley first reported a position in KITE in Q3 2014 and held it in 13 quarters. The position peaked at $88M in Q3 2017. 0 funds tracked by Wall St. Rank hold KITE as of Q4 2017.

  • Morgan Stanley reported no remaining Kite Pharma, Inc. position as of Q4 2017 after selling out during the quarter.
  • Morgan Stanley sold 489,605 Kite Pharma, Inc. shares in Q4 2017, an estimated $88M.
  • Morgan Stanley first reported a position in Kite Pharma, Inc. in Q3 2014 and held it in 13 quarters.
  • Morgan Stanley's Kite Pharma, Inc. position peaked at $88M in Q3 2017.
  • 0 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q4 2017.

Based on Morgan Stanley's 13F filing for Q4 2017, filed 14 Feb 2018.